I agree that this site is using cookies. You can find further informations here.
X
Tatsumi, Tomohide
293  results:
Search for persons X
?
1

Clinical factors associated with the therapeutic efficacy o..:

Kai, Machiko ; Hikita, Hayato ; Kazuki, Maesaka...
PLOS ONE.  19 (2024)  1 - p. e0294590 , 2024
Link: https://doi.org/10.1371/..
 
?
2

Proteomic analysis of serum extracellular vesicles reveals ..:

Sakane, Sadatsugu ; Hikita, Hayato ; Shirai, Kumiko...
Hepatology Communications.  8 (2024)  6 - p. , 2024
Link: https://doi.org/10.1097/..
 
?
3

The relationship between observation interval and prognosis..:

Yoshioka, Teppei ; Shigekawa, Minoru ; Ikezawa, Kenji...
Pancreatology.  24 (2024)  1 - p. 73-77 , 2024
Link: https://doi.org/10.1016/..
 
?
4

Genome‐wide loss‐of‐function genetic screen identifies INSI..:

Fukuoka, Makoto ; Kodama, Takahiro ; Murai, Kazuhiro...
Cancer Science.  115 (2024)  3 - p. 859-870 , 2024
Link: https://doi.org/10.1111/..
 
?
5

THU-413 Baseline gamma-glutamyl transpeptidase levels are a..:

Tahata, Yuki ; Hikita, Hayato ; Mochida, Satoshi...
Journal of Hepatology.  80 (2024)  - p. S828-S829 , 2024
Link: https://doi.org/10.1016/..
 
?
6

Featured Cover:

Kumazaki, Shusuke ; Hikita, Hayato ; Tahata, Yuki...
Alimentary Pharmacology & Therapeutics.  60 (2024)  3 - p. , 2024
Link: https://doi.org/10.1111/..
 
?
7

TOP-288 Serum GDF15 level, in combination with the FIB-4 in..:

Hikita, Hayato ; Kumazaki, Shunsuke ; Tahata, Yuki...
Journal of Hepatology.  80 (2024)  - p. S506-S507 , 2024
Link: https://doi.org/10.1016/..
 
?
8

The serum tenascin C level is a marker of metabolic disorde..:

Sato, Katsuhiko ; Hikita, Hayato ; Shigekawa, Minoru...
Scientific Reports.  14 (2024)  1 - p. , 2024
Link: https://doi.org/10.1038/..
 
?
9

Serum growth differentiation factor 15 is a novel biomarker..:

Kumazaki, Shusuke ; Hikita, Hayato ; Tahata, Yuki...
Alimentary Pharmacology & Therapeutics.  60 (2024)  3 - p. 327-339 , 2024
Link: https://doi.org/10.1111/..
 
?
10

S2 Fig -:

Machiko Kai ; Hayato Hikita ; Maesaka Kazuki...
doi:10.1371/journal.pone.0294590.s002.  , 2024
Link: https://doi.org/10.1371/..
 
?
11

Patient characteristics:

Machiko Kai ; Hayato Hikita ; Maesaka Kazuki...
doi:10.1371/journal.pone.0294590.t001.  , 2024
Link: https://doi.org/10.1371/..
 
?
12

S1 Data -:

Machiko Kai ; Hayato Hikita ; Maesaka Kazuki...
doi:10.1371/journal.pone.0294590.s004.  , 2024
Link: https://doi.org/10.1371/..
 
?
13

S1 Fig -:

Machiko Kai ; Hayato Hikita ; Maesaka Kazuki...
doi:10.1371/journal.pone.0294590.s001.  , 2024
Link: https://doi.org/10.1371/..
 
?
14

Fig 3 -:

Machiko Kai ; Hayato Hikita ; Maesaka Kazuki...
doi:10.1371/journal.pone.0294590.g003.  , 2024
Link: https://doi.org/10.1371/..
 
?
15

Treatment-related adverse events:

Machiko Kai ; Hayato Hikita ; Maesaka Kazuki...
doi:10.1371/journal.pone.0294590.t004.  , 2024
Link: https://doi.org/10.1371/..
 
1-15